drugset / Trial / NCT04325581

Laparocopic Sleeve Gastrectomy With or Without Liraglutide in Obese Patients

NCT04325581

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Investigators postulate that the metabolic effects of LSG would be augmented with the use of liraglutide leading to additional excess weight loss, improved glucose homeostasis, decreased intrapancreatic and intrahepatic fat than either of them individually. However there are no studies till date which have evaluated the combined effects of two modalities of weight loss on the above mentioned parameters. This study plans to compare the effects of liraglutide in post- LSG obese patients in a placebo controlled design.

Timeline

Start
2016-08-01
Primary completion
2018-12-31
Completion
2018-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Liraglutide Peptide 1.8 mg Subcutaneous

Indications

No indication recorded.